Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients With Relapsed or Refractory CD19 Positive B Cell Malignancies

NCT03853616 is registered in ClinicalTrials.gov with Miltenyi Biomedicine GmbH as lead sponsor.

NCT NCT03853616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03853616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients With Relapsed or Refractory CD19 Positive B Cell Malignancies
Lead sponsor
Miltenyi Biomedicine GmbH
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 26, 2018
Completion date
November 30, 2026
Enrollment
48 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia recurrent, b-cell lymphoma recurrent, b-cell lymphoma refractory, chronic lymphocytic leukemia recurrent, chronic lymphocytic leukemia refractory